Five Years' Experience Treating Locally Advanced Cervical Cancer With Concurrent Chemoradiotherapy and High-Dose-Rate Brachytherapy: Results From a Single Institution

International Journal of Radiation Oncology Biology Physics

Volumn 74, Issue 1, 2009, Pages 140-146

  Parker, Kate ^a   Gallop Evans, Eve ^a   Hanna, Louise ^a   Adams, Malcolm ^a  

^a VELINDRE CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRACHYTHERAPY; CERVICAL CANCERS; CHEMOTHERAPY TREATMENTS; CISPLATIN; CLINICAL OUTCOMES; CONCURRENT CHEMORADIOTHERAPY; CONCURRENT CISPLATIN; HEMOGLOBIN LEVELS; HIGH-DOSE-RATE BRACHYTHERAPY; KAPLAN-MEIER; LOCAL CONTROLS; LYMPH NODES; MULTI-VARIATE ANALYSIS; OVERALL SURVIVALS; PRE TREATMENTS; PROGNOSTIC FACTORS; PROGNOSTIC VARIABLES; PROPORTIONAL HAZARDS MODELS; SIDE EFFECTS; TUMOR SIZES;

BODY FLUIDS; CHEMOTHERAPY; COMPUTER OPERATING SYSTEMS; DECISION MAKING; HEMOGLOBIN; PLATINUM COMPOUNDS;

MULTIVARIANT ANALYSIS;

CISPLATIN; HEMOGLOBIN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER CONTROL; COHORT ANALYSIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HEMOGLOBIN A; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR BURDEN; UTERINE CERVICAL NEOPLASMS;

EID: 64049095821     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.06.1920     Document Type: Article

References (31)

1. Office for National Statistics. Cancer statistics registrations: Registration of cancer diagnosed in 2004, England. Series MB1 Number 35 (2004), Office for National Statistics, London
2. Welsh Cancer Intelligence and Surveillance Unit. WCISU Annual Publication No. SA6/02: Cancer incidence in Wales 2001-2005. Welsh Cancer Intelligence and Surveillance Unit; 2006.
3. Scottish Cancer Registry. Statistical Publication Notice, 29th May 2007, National Statistics, Cancer Incidence (2004). Scottish Cancer Registry; 2007.
4. Northern Ireland Cancer Registry. Cervix uteri (ICD10 C53) incidence 1993-2005. Available from: http://www.qub.ac.uk/nicr/. Accessed January 2007.
5. Keys H.M., Bundy B.N., Stehman F.B., et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage 1B cervical cancer. N Engl J Med 340 (1999) 1154-1161
6. Whitney C.W., Sause W., Bundy B.N., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative lymph nodes: A Gynecologic Oncology and Southwest Oncology Group study. J Clin Oncol 17 (1999) 1339-1348
7. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340 (1999) 1137-1143
8. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340 (1999) 1144-1153
9. Peters III W.A., Liu P.Y., Barrett II R.J., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation alone as adjuvant therapy after radical surgery in high-risk early stage cancer of the cervix. J Clin Oncol 18 (2000) 1606-1613
10. Thomas G.M. Improved treatment for cervical cancer-Concurrent chemotherapy and radiotherapy. N Engl J Med 340 (1999) 1198-1200
11. Green J.A., Kirwan J.M., Tierney J.F., et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix; a systematic review and meta-analysis. Lancet 358 (2001) 781-786
12. Lukka H., Hirte H., Fyles A., et al. Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer-A meta-analysis. Clin Oncol 14 (2002) 203-212
13. Lertsanguansinchai P., Lertbutsayanukul C., Shotelersuk K., et al. Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma. Int J Radiat Oncol Biol Phys 59 (2004) 1424-1431
14. Patel F.D., Sharma S.C., Negi P.S., et al. Low dose rate vs. high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: A clinical trial. Int J Radiat Oncol Biol Phys 28 (1994) 335-341
15. Hareyama M., Sakata K., Oouchi A., et al. High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix: A randomized trial. Cancer 94 (2002) 117-124
16. el Baradia M.M., Inoue T., Inoue T., et al. High dose rate and medium dose rate brachytherapy for carcinoma of the uterine cervix: Five-year clinical experience of Osaka University Hospital. J Brachyther Int 13 (1997) 261-269
17. Lorvidhaya V., Tonusin A., Changwiwit W., et al. High-dose-rate afterloading brachytherapy in carcinoma of the cervix: An experience of 1992 patients. Int J Radiat Oncol Biol Phys 46 (2000) 1185-1191
18. Chatani M., Matayoshi Y., Masaki N., et al. Long term follow up results of high dose rate remote afterloading intracavitary radiation therapy for carcinoma of the uterine cervix. Strahlenther Onkol 170 (1994) 260-276
19. Nakano T., Kato S., Ohno T., et al. Long-term results of high dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix. Cancer 103 (2005) 92-101
20. National Institute for Health and Clinical Excellence. High dose rate brachytherapy for carcinoma of the cervix (2006), National Institute for Health and Clinical Excellence, London
21. National Cancer Institute. Common toxicity criteria for adverse events, v3.0 (CTCAE) (2003), National Cancer Institute, Bethesda
22. Fowler J.F. The linear quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62 (1989) 679-694
23. Board of Faculty Clinical Oncology The Royal College of Radiologists. Guidelines for the management of the unscheduled interruption or prolongation of a radical course of radiotherapy. 2nd ed. (2002), Royal College of Radiologists, London
24. In: Meredith W.J. (Ed). Radium dosage: The Manchester system (1967), Livingstone, Edinburgh
25. Pearcey R., Brudage M., Drouin P., et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 20 (2002) 966-972
26. Denton A.S., Bond S.J., Matthews S., et al. National Audit of the Management and outcome of carcinoma of the cervix treated with radiotherapy in 1993. Clin Oncol (R Coll Radiol) 12 (2000) 347-353
27. Atahan I.L., Onal C., Ozyar E., et al. Long-term outcome and prognostic factors in patients with cervical carcinoma: A retrospective study. Int J Gynecol Cancer 17 (2007) 833-842
28. Toita T., Moromizato H., Ogarwa K., et al. Concurrent chemoradiotherapy using high dose rate intracavitary brachytherapy for uterine cervical cancer. Gynecol Oncol 96 (2005) 665-670
29. Souhami L., Seymour R., Roman T.N., et al. Weekly cisplatin plus external beam radiotherapy and high dose rate brachytherapy in patients with locally advanced carcinoma of the cervix. Int J Radiat Oncol Biol Phys 27 (1993) 871-878
30. Novetsky A.P., Einstein M.H., Goldberg G.L., et al. Efficacy and toxicity of concomitant cisplatin with external beam pelvic radiotherapy and two high-dose-rate brachytherapy insertions for treatment of locally advanced cervical cancer. Gynecol Oncol 105 (2007) 635-640
31. Lanciano R.M., Pajak T.F., Martz K., et al. The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: A Patterns-of-Care study. Int J Radiat Oncol Biol Phys 25 (1993) 391-397